Researchers track Long-Term safety of rare blood disorder treatment
NCT ID NCT07413679
Summary
This study is observing the long-term safety of adding a medication called danicopan to standard treatments for adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disease. It will follow about 50 patients already taking this combination therapy to monitor for serious side effects and infections. The goal is to better understand the safety profile of this treatment approach over time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alexion Pharmaceuticals, Inc. (Sponsor)
Boston, Massachusetts, 02210, United States
Conditions
Explore the condition pages connected to this study.